Medpace Holdings Inc (MEDP)
392.57
+1.50
(+0.38%)
USD |
NASDAQ |
May 03, 16:00
392.78
+0.21
(+0.05%)
After-Hours: 20:00
Medpace Holdings Cash from Financing (Quarterly): 7.66M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 7.66M |
| December 31, 2023 | 1.523M |
| September 30, 2023 | -49.27M |
| June 30, 2023 | -82.21M |
| March 31, 2023 | -52.68M |
| December 31, 2022 | -131.12M |
| September 30, 2022 | -109.11M |
| June 30, 2022 | -123.46M |
| March 31, 2022 | -412.08M |
| December 31, 2021 | 2.431M |
| September 30, 2021 | -5.207M |
| June 30, 2021 | -50.78M |
| March 31, 2021 | 9.102M |
| December 31, 2020 | -40.21M |
| September 30, 2020 | 6.777M |
| June 30, 2020 | -8.406M |
| March 31, 2020 | -40.44M |
| December 31, 2019 | 0.834M |
| September 30, 2019 | 1.795M |
| Date | Value |
|---|---|
| June 30, 2019 | -53.52M |
| March 31, 2019 | -23.03M |
| December 31, 2018 | -33.85M |
| September 30, 2018 | -49.75M |
| June 30, 2018 | -33.98M |
| March 31, 2018 | -24.01M |
| December 31, 2017 | -23.23M |
| September 30, 2017 | -42.14M |
| June 30, 2017 | -29.14M |
| March 31, 2017 | -3.305M |
| December 31, 2016 | -3.136M |
| September 30, 2016 | -39.19M |
| June 30, 2016 | -15.30M |
| March 31, 2016 | -0.38M |
| December 31, 2015 | -50.38M |
| September 30, 2015 | -0.411M |
| June 30, 2015 | -35.41M |
| March 31, 2015 | -30.29M |
| March 31, 2014 | -17.97M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-412.08M
Minimum
Mar 2022
9.102M
Maximum
Mar 2021
-56.42M
Average
-40.33M
Median
Cash from Financing (Quarterly) Benchmarks
| Charles River Laboratories International Inc | 123.57M |
| Avid Bioservices Inc | 0.085M |
| Iovance Biotherapeutics Inc | 0.962M |
| Renovaro Inc | 2.847M |
| Candel Therapeutics Inc | -0.121M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 152.68M |
| Cash from Investing (Quarterly) | 2.53M |
| Free Cash Flow | 473.34M |
| Free Cash Flow Per Share (Quarterly) | 4.599 |
| Free Cash Flow to Equity (Quarterly) | 147.18M |
| Free Cash Flow to Firm (Quarterly) | 147.18M |
| Free Cash Flow Yield | 3.79% |